Joint Bone Spine最新文献

{"title":"Imaging in the assessment of deposits in gout: From research to daily clinical implementation","authors":"Tristan Pascart","doi":"10.1016/j.jbspin.2025.105897","DOIUrl":"10.1016/j.jbspin.2025.105897","url":null,"abstract":"","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"92 6","pages":"Article 105897"},"PeriodicalIF":3.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143789352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global, regional, and national burden of gout in people aged 15–39 years from 1990 to 2021: Trends, cross-country inequalities and forecast to 2035","authors":"Yinglun Zhang ,&nbsp;Zhibin Jin ,&nbsp;Jing Yao ,&nbsp;Dandan Wang ,&nbsp;Yunxian Yu ,&nbsp;Weijing Zhang","doi":"10.1016/j.jbspin.2025.105929","DOIUrl":"10.1016/j.jbspin.2025.105929","url":null,"abstract":"<div><h3>Objectives</h3><div>To evaluate the trends and cross-country inequalities of gout burden in people aged 15–39 years from 1990 to 2021, with projections to 2035.</div></div><div><h3>Methods</h3><div>The study employed estimates from Global Burden of Diseases (GBD) 2021 to assess prevalence, incidence, and years lived with disability (YLDs) of gout across global, demographic, GBD regional, national, sociodemographic index (SDI) regional, and risk factor levels. Temporal trends in the age-standardized rates (ASRs) of prevalence, incidence and YLDs were assessed by Joinpoint regression, while associations between SDI and ASRs were examined through Spearman correlation. Health inequalities were measured using the slope index of inequality and the concentration index. Future trends were forecast by a Bayesian age-period-cohort model.</div></div><div><h3>Results</h3><div>The burden of gout increased in global, demographic, GBD regional, and SDI level from 1990 to 2021. Males, the 35–39 years subgroup, and High-SDI regions experienced the highest burden. High-income North America owned the highest ASRs while East Asia reported the largest numbers. A moderate positive correlation was observed between gout burden and SDI for nations. Both absolute and relative inequalities increased. Males had higher YLDs due to high body mass index (BMI), females due to kidney dysfunction. Although ASRs were predicted to decrease from 2020 to 2035, numbers were predicted to rise.</div></div><div><h3>Conclusions</h3><div>The gout burden gout in people aged 15–39 years increased with notable inequalities. Despite projected ASRs decreases, overall numbers were likely to increase, highlighting the urgent need for targeted interventions and public health strategies.</div></div>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"92 6","pages":"Article 105929"},"PeriodicalIF":3.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144175885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantitative HRCT as a surrogate outcome measure for nintedanib treatment in systemic sclerosis-interstitial lung disease and idiopathic pulmonary fibrosis","authors":"Marco Di Battista ,&nbsp;Chiara Romei ,&nbsp;Laura Tavanti ,&nbsp;Vincenzo Uggenti ,&nbsp;Sara Mitolo ,&nbsp;Edoardo Airò ,&nbsp;Francesco Pistelli ,&nbsp;Davide Chimera ,&nbsp;Laura Carrozzi ,&nbsp;Emanuele Neri ,&nbsp;Annalisa De Liperi ,&nbsp;Alessandra Della Rossa ,&nbsp;Marta Mosca","doi":"10.1016/j.jbspin.2025.105934","DOIUrl":"10.1016/j.jbspin.2025.105934","url":null,"abstract":"<div><h3>Objective</h3><div>We assessed the effect of nintedanib (NIN) in terms of quantitative HRCT changes in both idiopathic pulmonary fibrosis (IPF) and systemic sclerosis-associated progressive interstitial lung disease (SSc-ILD), evaluating the relationships between imaging variations and clinical-functional outcomes.</div></div><div><h3>Methods</h3><div>We prospectively enrolled SSc-ILD and IPF patients treated with NIN and retrospectively selected the same number of subjects from a historical untreated cohort comparable for disease, age, gender and follow-up period. HRCT scans were processed with CALIPER software, obtaining the percentage of normal parenchyma, ILD and vascular-related structures (VRS).</div></div><div><h3>Results</h3><div>Quantitative HRCT changes of 36 NIN treated patients (12 SSc-ILD and 24 IPF) were compared with 36 untreated subjects with pulmonary fibrosis. After a mean follow-up period of 22 months, NIN therapy was associated with a percentage stabilization of normal parenchyma (from 81.3<!--> <!-->±<!--> <!-->11.8% to 78.6<!--> <!-->±<!--> <!-->15.6%; <em>P</em> <!-->=<!--> <!-->not significant) and ILD (from 14.5<!--> <!-->±<!--> <!-->10.4% to 16.7<!--> <!-->±<!--> <!-->14.2%; <em>P</em> <!-->=<!--> <!-->not significant) both in SSc-ILD and IPF, avoiding the loss of normal parenchyma (from 87.4<!--> <!-->±<!--> <!-->7.3% to 78.8<!--> <!-->±<!--> <!-->16.7%; <em>P</em> <!-->&lt;<!--> <!-->0.001) and ILD worsening (from 9.0<!--> <!-->±<!--> <!-->5.9% to 16.5<!--> <!-->±<!--> <!-->14.8%; <em>P</em> <!-->&lt;<!--> <!-->0.001) observed in the untreated cohort. VRS was significantly increased regardless of antifibrotic therapy (<em>P</em> <!-->&lt;<!--> <!-->0.001). NIN treated patients who experienced a clinically meaningful worsening at pulmonary function tests or at the reported dyspnoea, presented a significant loss of normal parenchyma in parallel with a greater increase in ILD (<em>P</em> <!-->&lt;<!--> <!-->0.05 for all).</div></div><div><h3>Conclusion</h3><div>NIN appears effective in reducing the radiological decline of pulmonary fibrosis. Quantitative HRCT is proposed as a surrogate outcome measure for clinical practice and future trials.</div></div>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"92 6","pages":"Article 105934"},"PeriodicalIF":3.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144509507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics and outcomes of elderly patients with ANCA-associated vasculitis","authors":"Elif Durak Ediboğlu ,&nbsp;Hasan Kocaayan ,&nbsp;Önay Gercik ,&nbsp;Zeki Soypaçacı ,&nbsp;Dilek Solmaz ,&nbsp;Servet Akar","doi":"10.1016/j.jbspin.2025.105962","DOIUrl":"10.1016/j.jbspin.2025.105962","url":null,"abstract":"","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"92 6","pages":"Article 105962"},"PeriodicalIF":4.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145024722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IL-6: A new target in crystal-induced arthritides – A narrative review","authors":"Augustin Latourte ,&nbsp;Tristan Pascart ,&nbsp;Pascal Richette","doi":"10.1016/j.jbspin.2025.105935","DOIUrl":"10.1016/j.jbspin.2025.105935","url":null,"abstract":"<div><div>Gout and calcium pyrophosphate deposition disease (CPPD) are two highly prevalent causes of inflammatory arthritis, characterized by the pathological deposition of monosodium urate (MSU) and CPP crystals, respectively, in joint tissues. These crystals can induce an intense inflammatory response, known as crystal-induced inflammation, which involves innate immunity and is highly dependent of the activation of interleukin 1β (IL-1β) following the recruitment of the NLRP3 inflammasome. In patients in whom first-line treatments (colchicine, prednisone, NSAIDs) are either ineffective or inappropriate, IL-1 inhibitors can be used to treat acute crystal-induced arthritis. However, some patients do not respond to these therapies, or experience adverse events. There is therefore a need for other treatments, particularly in CPPD, where the inflammation induced by CPP crystals can be chronic and affect elderly patients, making IL-1 inhibitors a less suitable option. IL-6, which is highly expressed during crystal-induced inflammation, is emerging as a promising therapeutic target in chronic CPP arthritis, with publications reporting the efficacy of tocilizumab in patients with inadequate response to other treatments, including anakinra, the most commonly used IL-1 inhibitor in this indication (off-label). These data require confirmation in randomized controlled trials. Other therapies, such as JAK inhibitors or NLRP3 inhibitors, may also be of interest in crystal-induced arthritis.</div></div>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"92 6","pages":"Article 105935"},"PeriodicalIF":3.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic accuracy and trajectories of referrals for gout to rheumatology","authors":"Timothy S.H. Kwok ,&nbsp;Sangeeta Bajaj ,&nbsp;Tripti Papneja ,&nbsp;Vandana Ahluwalia ,&nbsp;Gregory Choy ,&nbsp;Raman Joshi","doi":"10.1016/j.jbspin.2025.105919","DOIUrl":"10.1016/j.jbspin.2025.105919","url":null,"abstract":"<div><h3>Objectives</h3><div>To evaluate diagnostic accuracy and trajectories of gout referrals to rheumatology including factors associated with an accurate diagnosis.</div></div><div><h3>Methods</h3><div>We performed a retrospective cohort study of referrals at 4 rheumatology clinics in Brampton, Canada from December 2019 to January 2023. We assessed gout diagnostic accuracy referenced to the rheumatologist's “gold standard” diagnosis, describing alternative final diagnoses. Using multivariable logistic regression, we identified factors associated with an accurate gout diagnosis.</div></div><div><h3>Results</h3><div>Among 4315 patients, 216 were diagnosed with gout. Of 191 gout referrals (mean (SD) age 58.4 (15.4) years; 77.0% male), the diagnosis was unchanged in 159 (83.2%) patients with alternative diagnoses comprising osteoarthritis, autoimmune inflammatory arthritis and calcium pyrophosphate deposition disease. Referring physicians had moderate-to-high sensitivity (73.6%, 95% CI: 67.2–79.4), specificity (99.2%, 95% CI: 98.9–99.5), positive predictive value (83.2%, 95% CI: 77.2–88.2), negative predictive value (98.6%, 95% CI: 98.2–99.0) and inter-rater reliability (Cohen's kappa: 0.77, 95% CI: 0.72–0.82). Accuracy was highest amongst internists and emergency room physicians. Male sex (OR 14.32, 95% CI: 4.44–46.17), serum urate ≥<!--> <!-->500<!--> <!-->μmol/L (OR 9.10, 95% CI: 2.19–7.78), lower extremity monoarthritis (OR 5.08, 95% CI: 1.59–16.27) and symptom duration ≤<!--> <!-->2<!--> <!-->weeks (OR 3.87, 95% CI 1.23–12.21) were predictive of a final gout diagnosis.</div></div><div><h3>Conclusions</h3><div>Referring providers had reasonably high accuracy in diagnosing gout. Traditional risk factors were associated with concordance with the consultant rheumatologist. Suboptimal gout care likely does not stem at point-of-diagnosis and quality improvement efforts should be focused on mitigating treatment-associated care gaps.</div></div>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"92 6","pages":"Article 105919"},"PeriodicalIF":3.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144043188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early peripheral psoriatic arthritis: Baseline features of the first 186 patients in the French Nationwide APACHE Cohort","authors":"Pascal Claudepierre ,&nbsp;Cecile Gaujoux-Viala ,&nbsp;Arnaud Constantin ,&nbsp;Francis Berenbaum ,&nbsp;Bernard Combe ,&nbsp;Valerie Devauchelle ,&nbsp;Philippe Goupille ,&nbsp;Pascal Richette ,&nbsp;Daniel Wendling ,&nbsp;Gael Mouterde ,&nbsp;Tristan Pascart ,&nbsp;Benedicte Razat ,&nbsp;Etienne Audureau ,&nbsp;Sandrine Jousse-Joulin ,&nbsp;Laure Gossec","doi":"10.1016/j.jbspin.2025.105930","DOIUrl":"10.1016/j.jbspin.2025.105930","url":null,"abstract":"<div><h3>Objectives</h3><div>To describe the design and methodology of APACHE, a cohort of patients with early peripheral psoriatic arthritis (pPsA), and to assess the main baseline clinical characteristics of the first included patients.</div></div><div><h3>Methods</h3><div>APACHE is an ongoing prospective multicentre national cohort (<span><span>NCT03768271</span><svg><path></path></svg></span>) with a planned follow-up of 10<!--> <!-->years. Included patients have recent-onset (&lt;<!--> <!-->12<!--> <!-->months) peripheral arthritis, a personal and/or family history of psoriasis, pPsA diagnosed by a rheumatologist, and no history of targeted disease-modifying antirheumatic drug therapy. At inclusion, demographic data, disease activity, comorbidities, and imaging results (not reported here) are collected. A descriptive analysis of these data was performed.</div></div><div><h3>Results</h3><div>The first 186 study patients had a mean age of 44<!--> <!-->±<!--> <!-->11<!--> <!-->years and mean arthritis duration of 6<!--> <!-->±<!--> <!-->4<!--> <!-->months; 84 (45%) were women; 169 (91%) had a history of psoriasis (mean duration, 14<!--> <!-->years) and 71 (38%) were receiving methotrexate. Disease activity was moderate with a mean DAPSA score of 19<!--> <!-->±<!--> <!-->14 and mean swollen and tender joint counts of 2.1<!--> <!-->±<!--> <!-->3.2 and 6.0<!--> <!-->±<!--> <!-->8.0, respectively. The initially involved joints were mainly the hands (40%) and knees (28%). Entheseal pain (39%) was more prevalent than dactylitis (27%). Comorbidities were common, with obesity in 27% and at least one cardiovascular risk factor or disease in 49% of patients.</div></div><div><h3>Conclusion</h3><div>Patients with early peripheral PsA had moderate disease activity, a predominant oligoarticular profile, and a high prevalence of entheseal pain.</div></div>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"92 6","pages":"Article 105930"},"PeriodicalIF":3.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144181782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Muscle in axial spondyloarthritis: Culprit or victim?","authors":"Daniel Wendling,&nbsp;Frank Verhoeven,&nbsp;Clément Prati","doi":"10.1016/j.jbspin.2025.105899","DOIUrl":"10.1016/j.jbspin.2025.105899","url":null,"abstract":"","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"92 6","pages":"Article 105899"},"PeriodicalIF":3.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143789353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of the gut and intestinal dysbiosis in the pathogenesis of spondyloarthritis","authors":"Daniele Mauro ,&nbsp;Benjamin Cai ,&nbsp;Antonio Ciancio ,&nbsp;Giulio Forte ,&nbsp;Saviana Gandolfo ,&nbsp;Ranjeny Thomas ,&nbsp;Anne-Sophie Bergot ,&nbsp;Francesco Ciccia","doi":"10.1016/j.jbspin.2025.105923","DOIUrl":"10.1016/j.jbspin.2025.105923","url":null,"abstract":"<div><div>Spondyloarthritis (SpA) encompasses chronic inflammatory diseases affecting both axial and peripheral joints. Emerging evidence highlights a pivotal role for the gut–joint axis in SpA pathogenesis, where intestinal dysbiosis and barrier dysfunction facilitate microbial translocation and trigger systemic immune activation. Clinical observations of subclinical gut inflammation, alongside findings from HLA-B27 transgenic rats and SKG mice, underscore the gut's role in initiating joint pathology. Genetic predispositions, particularly HLA-B27, further exacerbate these processes through mechanisms such as endoplasmic reticulum stress and IL-23-mediated T-cell activation. This review integrates epidemiological, mechanistic, and experimental insights to elucidate the complex interplay between the gut microbiota and immune responses in SpA, outlining potential avenues for targeted intervention.</div></div>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"92 6","pages":"Article 105923"},"PeriodicalIF":3.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144129517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pyomyositis of the obturator internus muscle","authors":"Théo Renaud ,&nbsp;Adrien Le Pluart ,&nbsp;Paul Arnolfo ,&nbsp;Christelle Darrieutort-Laffite","doi":"10.1016/j.jbspin.2025.105979","DOIUrl":"10.1016/j.jbspin.2025.105979","url":null,"abstract":"","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"92 6","pages":"Article 105979"},"PeriodicalIF":4.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145187449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}